Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis

Current Drug Targets. CNS and Neurological Disorders
C A Tamminga, A Carlsson

Abstract

The early demonstration of chlorpromazine efficacy in schizophrenia and its subsequent identification as a dopamine receptor antagonist, established the only known mechanism for antipsychotic development to date. By extension, it is easy to hypothesize that any mechanism shown to reduce dopamine-mediated transmission in brain will have antipsychotic properties. The evaluation of partial dopamine agonists for antipsychotic efficacy and their application in the treatment of psychosis has derived from this background. Partial dopamine agonists at the D2 dopamine receptor, have high affinity for that receptor, but reduced intrinsic activity. These agonists have higher affinity for the presynaptic autoreceptor than for the postsynaptic receptor. Hence, these compounds reduce dopamine synthesis and release through an agonist action at the dopamine autoreceptor. Moreover, the agonists have lower intrinsic activity at the postsynaptic receptor than its natural ligand dopamine. Therefore, they diminish the dopaminergic signal at postsynaptic sites as well through delivering a reduced message; this component of drug action becomes more prominent the lower the intrinsic activity of the drug. Several partial dopamine agonists have been eva...Continue Reading

Citations

Mar 27, 2012·European Child & Adolescent Psychiatry·Eiji Kirino
May 26, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Johan P RungMaria L Carlsson
Nov 30, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·William T Carpenter, James I Koenig
Feb 19, 2009·Schizophrenia Bulletin·S Hossein Fatemi, Timothy D Folsom
Feb 14, 2004·The Australian and New Zealand Journal of Psychiatry·Brian Dean
May 10, 2011·Neuropsychiatric Disease and Treatment·Meghan E McIlwainBruce R Russell
Nov 10, 2010·Naunyn-Schmiedeberg's Archives of Pharmacology·Beryl KoenerEmmanuel Hermans
Sep 28, 2010·Annual Review of Pharmacology and Toxicology·Hisham M Ibrahim, Carol A Tamminga
Mar 14, 2007·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Manon LebelMichel Cyr
Dec 24, 2013·Future Medicinal Chemistry·Pawel ZajdelAnna Wesolowska
Jul 20, 2012·International Journal of Psychiatry in Clinical Practice·Luiz DratcuMartin Turner
Dec 1, 2006·Expert Opinion on Drug Discovery·Terry Kenakin
Jan 25, 2011·Expert Opinion on Pharmacotherapy·Andrea FagioliniFrancesco Casamassima
Jul 11, 2009·Expert Opinion on Investigational Drugs·Robin Emsley
Feb 13, 2016·Trends in Pharmacological Sciences·Tsung-Ping SuShang-Yi Tsai
Mar 1, 2011·Bioorganic & Medicinal Chemistry Letters·Douglas S JohnsonKevin A Serpa
Feb 4, 2010·Parkinsonism & Related Disorders·Roberto MaggioMark J Millan
Aug 19, 2009·Psychosomatics·Juan UndurragaEduard Parellada
Mar 24, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ali CaykoyluElif Yilmaz
Nov 20, 2012·Basic & Clinical Pharmacology & Toxicology·Thercia G VianaFabricio A Moreira
Aug 7, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·James T TeoKailash Bhatia
Oct 24, 2006·European Journal of Pharmacology·Julia N HeinrichTerrance H Andree
Jul 11, 2006·Neurobiology of Learning and Memory·Lydia Giménez-LlortMichael Bader
Jun 21, 2005·Neuroscience and Biobehavioral Reviews·Urs MeyerBenjamin K Yee
Dec 3, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Roberto MaggioMark J Millan
Apr 1, 2011·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Na-Ri Kang, Moon-Doo Kim
Aug 30, 2011·Progress in Neuro-psychopharmacology & Biological Psychiatry·Beryl KoenerEmmanuel Hermans
Apr 29, 2014·Journal of Affective Disorders·Suhayl NasrJohn Crayton
Jul 17, 2007·Trends in Pharmacological Sciences·Richard B Mailman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here